MSD makes its obesity move with Hansoh deal
MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race but chose instead to back a runner from China's Hansh Pharma.
Merck signs deal worth up to $2 billion with China's Hansoh for oral obesity drug
Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's experimental oral obesity drug that works similar to the popular weight-loss treatments Wegovy and Zepbound.
Merck moves into obesity with deal for Hansoh’s GLP-1 pill
News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.
Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh
Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named HS-10535. It includes a $112 million licensing rights payment for global sales outside China.
Merck Snags Chinese Obesity Drug in Nearly $2 Billion Deal
Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.Under the terms of the deal, the company will gain the exclusive global license to develop,
Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion
Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company. Merck on Wednesday said it will make an upfront payment of $112 million to Hansoh in exchange for an exclusive global license to HS-10535,
Merck’s weight-loss pill deal: what it means for Eli Lilly
Merck & Co Inc (NYSE: MRK) is in focus this morning after announcing a $2.0 billion deal with Hansoh Pharma. The said agreement wins it rights to HS-10535 – an experimental weight-loss pill (oral) developed by the Chinese drugmaker.
Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers
Viking Therapeutics (NASDAQ:VKTX) and Structure Therapeutics (NASDAQ:GPCR) were among notable decliners on Wednesday after Merck (NYSE:MRK) partnered with Chinese biopharma Hansoh (OTCPK:HNSPF) to develop an oral GLP-1 receptor agonist for obesity and related conditions.
Reuters on MSN18h
Weight loss drugs could help end obesity - but risks remain, WHO says
LONDON (Reuters) - A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end ...
TCTMD17h
Obesity Trends May Be Going in the Right Direction for the First Time in a Decade
The US data suggest that the South has seen the greatest shifts, and the highest rate of GLP-1 prescribing per capita.
Politico Europe1h
Weight-loss drugs can help ‘reverse’ obesity pandemic, say WHO experts
Blockbuster weight-loss drugs can help to stop and reverse the global obesity crisis, experts from the World Health ...
Obesity giants will begin $80 bln M&A face-off
Eli Lilly and Novo Nordisk will kick off a massive shopping spree in 2025. The two obesity giants will be sitting on cash ...
Maryland Medicaid spent $68M in a year on obesity and diabetes drugs like Ozempic, Wegovy
Maryland’s Medicaid program now offers partial coverage of popular obesity drugs, with the state spending more than $68 ...
Medical Xpress on MSN19h
Some racial and ethnic groups may face barriers to obtaining obesity medications
Asians, non-Hispanic Blacks and Hispanics were significantly less likely than whites to use obesity-management medications ...
Science Daily2d
More calories -- more consumption: Individuals with and without obesity both prefer high-calories food, study finds
Higher calorie foods were preferred among individuals with and without obesity despite similar taste and texture, according to a new study. Higher calorie foods were preferred among individuals with ...
News Medical on MSN2d
Obesity prevalence and BMI decrease in the US for the first time in a decade
Obesity prevalence in the US decreased in 2023, with significant drops in the South, highlighting the impact of GLP-1RA ...
Pennsylvania Medicaid spent nearly $300 million on Wegovy and other anti-obesity drugs
Pennsylvania's Medicaid spending per enrollee on Wegovy, Zepbound and other anti-obesity drugs was third-highest in the ...
Obesity Rates in the U.S. Drop for the First Time in a Decade, ‘Proliferation’ of Ozempic May Be a Reason
Study authors point to semaglutide medication and “behavior changes” as possible reasons for the drop in obesity rates in the ...